Affordable Access

deepdyve-link
Publisher Website

Suitability of APINCH high-risk medications use in diabetes mellitus.

Authors
  • Zafar, Mohammad Ishraq1
  • 1 Institute of Reproductive Health, Tongji Medical College, Huazhong University of Science and Technology, 13 Hang Kong Street, 430030, Wuhan, PR China; Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, 430022, Wuhan, PR China. Electronic address: [email protected] , (China)
Type
Published Article
Journal
European journal of pharmacology
Publication Date
Dec 05, 2019
Volume
867
Pages
172845–172845
Identifiers
DOI: 10.1016/j.ejphar.2019.172845
PMID: 31812545
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

High-risk medicines are those that carry a high risk of causing fatal or serious injury if used in error. The globally used Institute for Safe Medication Practices's list of high-risk medicines refers to the general population without taking into account special populations, such as diabetic. By means of the literature search, the current review identified several medicines that were previously not included, and have the potential to cause harm to diabetes patients when used inappropriately, including fluoroquinolones, targeted cancer therapies, and tramadol. Additionally, this review identified risks that the included medicines may carry for diabetes patients, such as interactions between warfarin and sulfonylureas that may cause severe hypoglycemia or potentiation of gastrointestinal side effects with co-administration of opioids and various hypoglycemics. The proposed inclusions and respective recommendations are to be taken into consideration in diabetes care and help with the creation of high-risk medicine lists adapted to diabetes patients on an individual hospital level. Copyright © 2019 Elsevier B.V. All rights reserved.

Report this publication

Statistics

Seen <100 times